BlackRock Amends Supernus Pharma Stake as of Dec 31, 2023
Ticker: SUPN · Form: SC 13G/A · Filed: Jan 19, 2024 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | SC 13G/A |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**BlackRock updated its Supernus Pharma holdings, signaling a potential shift in institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 19, 2024, indicating its ownership of Supernus Pharmaceuticals Inc. common stock as of December 31, 2023. This amendment (Amendment No. 4) updates their previous holdings, signaling a potential change in their investment position. For investors, this matters because BlackRock is a major institutional investor, and changes in their stake can influence market sentiment and potentially the stock's price, reflecting their updated view on Supernus's prospects.
Why It Matters
This filing shows BlackRock's updated investment in Supernus Pharmaceuticals, which can signal institutional confidence or a shift in strategy, potentially impacting the stock's perceived value.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of institutional ownership and does not inherently present a direct risk to the company or its investors.
Analyst Insight
An investor should monitor subsequent filings from BlackRock or other major institutions to identify a clear trend in institutional ownership, as this filing alone doesn't specify the magnitude of change, only that an update occurred.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- SUPERNUS PHARMACEUTICALS, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 19, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 4 (number) — the specific amendment number of the filing
Forward-Looking Statements
- BlackRock's updated stake in Supernus Pharmaceuticals will be closely watched by other institutional investors. (BlackRock Inc.) — high confidence, target: Q1 2024
- The market sentiment for Supernus Pharmaceuticals may experience minor fluctuations following the disclosure of BlackRock's updated position. (SUPERNUS PHARMACEUTICALS, INC.) — medium confidence, target: January 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, specifically Amendment No. 4, filed under Rule 13d-1(b).
Which company is the subject of this filing?
The subject company is SUPERNUS PHARMACEUTICALS, INC., with CIK 0001356576 and CUSIP Number 868459108.
Who is the entity that filed this SC 13G/A?
The entity that filed this SC 13G/A is BlackRock Inc., with CIK 0001364742.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
What is the business address of Supernus Pharmaceuticals, Inc.?
The business address of Supernus Pharmaceuticals, Inc. is 9715 KEY WEST AVENUE, ROCKVILLE, MD 20850.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 19, 2024 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).